BSE List Price : ₹368.05

NSE List Price : ₹371.15

Subscription

Category	Times
QIBs	34.07x
HNIs	14.64x
Retail	3.04x
Employee	0.37x
Total : 14.21x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	1	43	₹14,792
Retail Maximum	13	559	₹192,296
S - HNI Minimum	14	602	₹207,088
S - HNI Maximum	67	2,881	₹991,064
B - HNI Minimum	68	2,924	₹1,005,856

About the Company

Sahajanand Medical Technologies Limited is a medical-device company headquartered in Surat, Gujarat. Established in 2001 as a company, it manufactures and distributes medical devices used in cardiovascular and vascular interventions. Its products are sold in India and international markets.

Business Model: The company develops, manufactures and distributes specialised medical devices to hospitals and healthcare distributors, with manufacturing operations in India and Thailand.

Products & Services

• Coronary stents

• Coronary balloon catheters

• Transcatheter aortic valve implantation (TAVI) devices

• Occluders for structural heart procedures

• Renal stents

• Peripheral drug-coated balloons

• Other interventional cardiology devices

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2024	₹908.59	₹875.50	₹-7.35	₹970.58
2025	₹1035.96	₹980.12	₹25.15	₹1094.90
2026	₹1218.73	₹1138.43	₹69.08	₹1276.43
June 2026	₹354.33	₹330.05	₹15.09	₹1308.100

Company Promoter

Bhargav Dhirajlal Kotadia

Dhirajlal Vallabhbhai Kotadia

Priyanka Dhirajlal Cohen

Shree Hari Trust

Know before investing

• • Strengths

  • Specialised Medical Devices: Focuses on high-technology cardiovascular and vascular-intervention products.

  • International Presence: Sells products in India and overseas markets.

  • Established Operations: Has experience in medical-device manufacturing and distribution.

  • Broad Product Portfolio: Serves both vascular-intervention and structural-heart treatment segments.

  • Revenue Growth: Consolidated revenue increased from 795.5 crore in FY2023 to 1,024.9 crore in FY2025.

• • Risks

  • Product Concentration: The Supraflex Cruz coronary stent contributed approximately 42.06% of FY2025 revenue.

  • Profitability Risk: The company reported a loss in FY2024 and relatively modest profit in FY2025.

  • Regulatory Requirements: Medical devices require regulatory approvals and compliance across different markets.

  • Competition: Faces competition from established international and domestic medical-device manufacturers.

  • Working Capital: The business has substantial working-capital requirements.

  • OFS-Only Issue: The IPO proceeds are for selling shareholders; the company will not receive fresh capital from the offer

Objects of the Issue & Utilisation of proceeds

• Offer for Sale (OFS): 1,38,22,116 equity shares.

• Total Issue Size: 475.48 crore.

• Fresh Issue: None.

• Utilisation of Proceeds: The proceeds will go to the selling shareholders. The company will not receive funds from the IPO.

• Purpose of Listing: To provide liquidity to existing shareholders and create a public market for the company's shares.

Company Address

Sahajanand Medical Technologies Ltd.
Sahajanand Estate, Wakharia Wadi,
NR. Dabholi Char Rasta
Nani Ved, Ved Road
Surat, Gujarat, 395004
Phone: 022 49564000
Email: investors.grievance@smt.in
Website: http://www.smtpl.com/

IPO Registrar

MUFG Intime India Pvt. Ltd.
Phone: 022-49186000
Email: sahajanandmedical.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html